StocktoriaLiminatus Pharma, Inc. LIMN
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances)
Chart by TradingView
1/9
Piotroski F — financial health
—
Altman Z″ — distress risk
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 |
|---|---|---|
| Financials | ||
| Operating income | -$3.0M | -$3.3M |
| Net income | -$10.2M | -$3.5M |
| Operating cash flow | -$10.0M | -$1.5M |
| Free cash flow | -$10.0M | — |
| Total assets | $512,795 | $5.4M |
| Total liabilities | $10.3M | $24.7M |
| Shareholders' equity | -$9.8M | -$19.3M |
| Ratios | ||
| Return on assets | -1990.4% | -65.6% |
| Return on equity | 104.0% | 18.3% |
| Current ratio | 0.05 | 0.21 |
Why these scores methodology →
Piotroski F-score: 1/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: n/a
Not applicable (financials/insurer or missing inputs).
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001971387 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.